{
    "organizations": [],
    "uuid": "bb039572ca3aff16afc3e544e2d52d6b51705919",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-five-prime-therapeutics-announces/brief-five-prime-therapeutics-announces-25-mln-payment-by-bristol-myers-squibb-idUSFWN1PK1N0",
    "ord_in_thread": 0,
    "title": "BRIEF-Five Prime Therapeutics Announces $25 Mln Payment By Bristol-Myers Squibb",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Five Prime Therapeutics Inc:\n* FIVE PRIME THERAPEUTICS ANNOUNCES $25 MILLION PAYMENT BY BRISTOL-MYERS SQUIBB FOR CABIRALIZUMAB DEVELOPMENT MILESTONE\n* FIVE PRIME THERAPEUTICS INC SAYS MILESTONE WAS TRIGGERED BY INITIATION OF A MULTI-ARM PHASE 2 CLINICAL TRIAL SPONSORED BY BRISTOL-MYERS SQUIBB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-26T05:20:00.000+02:00",
    "crawled": "2018-01-26T21:37:07.014+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "five",
        "prime",
        "therapeutic",
        "announces",
        "million",
        "payment",
        "squibb",
        "cabiralizumab",
        "development",
        "milestone",
        "five",
        "prime",
        "therapeutic",
        "inc",
        "say",
        "milestone",
        "triggered",
        "initiation",
        "phase",
        "clinical",
        "trial",
        "sponsored",
        "squibb",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}